Sellas Life Sciences Shares Rise 7.6% on Fast Track Designation for Cancer Treatment by FDA
By Denny Jacob
Sellas Life Sciences shares ticked up 7.6% to $1 following a fast track designation granted to SLS009 by the Food and Drug Administration.
The stock is down 57% this year, and hit a 52-week low last week
The late-stage clinical biopharmaceutical company's SLS009 is a CDK9 inhibitor for the treatment of relapsed/refractory peripheral T-cell lymphomas, a group of aggressive and rare non-Hodgkin lymphomas.
Sellas said it's also pursuing potential breakthrough therapy designation from the FDA for SLS009 to treat relapsed/refractory peripheral T-cell lymphomas. It has a scheduled meeting with the regulator in the fourth quarter.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 30, 2023 12:07 ET (16:07 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024